DIRS.INFO The most relevant business & tech news

☆ U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug
▼ + stars: | 2024-10-12 | by ( ) www.cnbc.com time to read: +1 min

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs. The compounding versions of the drugs are cheaper for patients than the brand-name versions. The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ingredient, tirzepatide, from its list of drugs experiencing shortages. Insurers generally cover drugs like tirzepatide for diabetes, but many do not cover them for weight loss.

Persons: Eli Lilly's, Mark Pittman Organizations: . Food, Drug Administration, Outsourcing, Association, District, FDA Locations: U.S, Fort Worth , Texas

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

☆ Here are Friday's biggest analyst calls: Nvidia, Tesla, Ferrari, Meta, Amazon, Eli Lilly, Walmart, Uber & more
▼ + stars: | 2024-10-11 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Goldman Sachs reiterates Nvidia as buy Goldman raised its price target to $150 per share from $135 following a series of Nvidia management meetings. Morgan Stanley names Atlassian a top pick Morgan Stanley named Atlassian a top idea and says the software company is well positioned for share gains. Morgan Stanley reiterates Eli Lilly as overweight Morgan Stanley raised its price target on the stock to $1,158 per share from $1,106. JPMorgan reiterates Amazon, Uber and Meta as top picks JPMorgan said in a note on Friday that Amazon, Uber and Meta were the firm's top three picks heading into earnings. JPMorgan upgrades Ferrari to overweight from neutral The firm says it's more constructive on the luxury automaker following a series of management meetings.

Persons: Wells, Redburn, Mercado, Morgan Stanley downgrades Qorvo, Morgan Stanley, Goldman Sachs, Goldman, Jensen Huang, Colette Kress, Stewart Stecker, Atlassian, Eli Lilly, LLY, Mizuho downgrades Mobileye, Kinder Morgan, it's bullish, Benedetto Vigna, Investor Relations Aldo Benetti, Tesla, Guggenheim Organizations: Bank of America, Broadcom, TAM, UBS, Devices, Mercado Libre, Nvidia, Pharma, Mizuho, JPMorgan, Meta, of America, Ferrari, Investor Relations, Netflix, Guggenheim, Walmart Locations: America, OW, China

☆ Friday's analyst calls: Goldman raises Nvidia target, JPMorgan upgrades Ferrari
▼ + stars: | 2024-10-11 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +4 min

(This is CNBC Pro's live coverage of Thursday's analyst calls and Wall Street chatter. Ferrari's scarcity-driven growth strategy has contributed to price growth of as much as 30% for new vehicles compared to prior vehicles, per Brinkman. — Hakyung Kim 6:25 a.m. Morgan Stanley raises Eli Lilly estimates Morgan Stanley notched its price target for Eli Lilly shares higher on increased weight-loss drug estimates. — Hakyung Kim 6:00: am Goldman Sachs raises Nvidia price target Goldman Sachs believes strong demand for artificial intelligence compute should help drive Nvidia shares higher. Analyst Toshiya Hari increased his price target on Nvidia shares to $150 from $135, implying 11.3% upside potential from Thursday's close.

Persons: Goldman, Morgan Stanley, Elli Lilly, Ryan Brinkman, Brinkman, Ferrari, — Hakyung Kim, Eli Lilly, Terence Flynn, Zepbound, Eli Lilly's, Mounjaro, Flynn, Mercado, Gonzalo Lopez, Lopez, Mercado Credito, Goldman Sachs, Toshiya Hari, Hari, Hakyung Kim Organizations: CNBC, Nvidia, JPMorgan, Ferrari, Mercado Libre, company's Data Locations: Thursday's, Latin America, U.S, America, verticals, Hari

Less than a fifth of large companies in the United States include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound in their health insurance plans, according to a survey published Wednesday in Health Affairs. “They’re trying to figure out what is the right balance between the advantages to employees, potential health benefits and the cost of these drugs. The survey found that about half of employers that cover the weight loss drugs have certain requirements associated with their coverage, which Rae said would limit access for some employees but save money. Among large firms that don’t currently cover GLP-1 drugs for weight loss, only about 3% said they’re “very likely” to do so in the next year. Despite the exorbitant cost, employers do have a positive view of the drugs.

Persons: Wegovy, ”, Matthew Rae, “ They’re, —, Rae, Susan Spratt, Christopher McGowan, Eli Lilly, ” McGowan, “, ” Rae, you’ve, that’s, don’t, they’re Organizations: Health Affairs, “ Employers, Population Health Management, Duke Health, Centers for Disease Control, Novo Nordisk, Research, North Carolina, ” Novo Nordisk Locations: United States, KFF, North Carolina, U.S, Novo

All four drugs are in a class of wildly popular weight loss drugs known as GLP-1s. In the United Kingdom, authorities last year seized hundreds of counterfeit Ozempic pens — insulin pens that had been relabeled as Ozempic. Counterfeit weight loss drugs have serious health risks, according to the pharmaceutical companies and federal officials. Counterfeiters are already trying to cash in on a weight loss drug that the company hasn't even put on the market yet: retatrutide. But it's also one of the epicenters of the lucrative counterfeit drug trade, according to U.S. authorities who track counterfeit drugs.

Persons: It's, —, Eli Lilly's Mounjaro, they've, Laver, Andy Morling, CNBC Morling, Eli Lilly, Daniel Skovronsky, Eli Lilly's, we'll, Skovronksy, John F, Sal Ingrassia, Ingrassia, Customs isn't, we've, Yoav Keren, GLP, TikTok, Keren, BrandShield, it's, Nicole Johnson, CNBC Johnson, Johnson, Mike Doustdar, Doustdar, Direnc Bada Organizations: CNBC, U.S, Laver Beauty, DHL, Novo Nordisk, Laver, Medicines, Healthcare Products Regulatory Agency, Lilly Research Labs, Kennedy International, JFK International Mail Facility, U.S . Customs, Border Protection, JFK, CBP, Protection, CNBC CNBC, FDA, Customs, Meta, Facebook, World Health Organization, U.S ., Intellectual, Coordination Center, National, Turkish National Police, Novo Nordisk's, CNBC Counterfeiters, CNBC FDA Locations: BOULDER, COLO, Boulder, Ozempic, Shijiazhuang, China, Beijing, Englewood Cliffs , New Jersey, United Kingdom, London, New York City, U.S, Turkey, Europe, South America, United States, India, Mexico, Istanbul, Zurich

☆ Bernstein upgrades Campbell as people taking GLP-1 drugs eating more soup
▼ + stars: | 2024-10-07 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Campbell Soup could be poised to benefit from an uptick in GLP-1 drug usage, according to Bernstein. Among the 20 analysts covering Campbell, only five have a strong buy or buy rating, while 12 have a hold rating. In addition, the analyst anticipates that reduced chocolate consumption from GLP-1 intake may hinder U.S. chocolate volumes by 2% to 3%. "Unfortunately, chocolate category volumes remain stubbornly negative and Hershey's chocolate volumes also remain weak despite lapping easier and easier comparables in recent months," Howard continued. Meanwhile, only four have a strong buy or buy rating, and its average target of $202.14 implies a gain of about 5% ahead.

Persons: Campbell, Bernstein, Eli Lilly's Mounjaro, Alexia Howard, Milano, Howard, they've Organizations: Nordisk's Ozempic, Hershey Locations: GLP

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ These are the most important stocks in the U.S., according to Bank of America
▼ + stars: | 2024-10-04 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

There are several key stocks in the U.S. investors need to be mindful of when navigating the current market environment, according to Bank of America. To capture the momentum from this rally, Bank of America screened for the most important stocks in each region of the world — including the U.S. — that have the potential to have the largest impact on portfolio performance, positive or negative. Bank of America found these stocks to be among the most important in the U.S.: Chipmaker Nvidia and oil and gas giant Exxon Mobil ranked fairly high on the firm's steady compounders list within the screen. Meta's shares are up nearly 64% year to date. Other stocks considered the most important names in the U.S. include rideshare company Uber and pharma name Eli Lilly .

Persons: Nigel Tupper, Vivek Arya's, Metaverse, Justin Post, Eli Lilly Organizations: Bank of America, Investment, U.S, Nvidia, Exxon Mobil, Exxon, Meta, Bank of America's, Uber Locations: U.S, Lebanon, Thursday's

☆ Calls of the Day: Tesla, Eli Lilly and Bank Of America
▼ + stars: | 2024-10-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Tesla, Eli Lilly and Bank Of AmericaThe Investment Committee debate the latest Calls of The Day.

Persons: Tesla, Eli Lilly Organizations: Bank, America, Investment

☆ How the port strike could actually boost Costco sales
▼ + stars: | 2024-10-03 | by ( Paulina Likos | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Club stock Nvidia jumped more than 3% — bucking the pressure on Big Tech. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jensen Huang, Eli Lilly, Lilly, Oppenheimer, Jim Cramer's, Jim Organizations: CNBC, Wall, Nvidia, Big Tech, Blackwell, Broadcom, Devices, Food and Drug Administration, Costco, AMD Locations: New Jersey

☆ 10 things to watch in the market Thursday, including great news from Nvidia's CEO
▼ + stars: | 2024-10-03 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

My top 10 things to watch Thursday, Oct. 3 Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. My top 10 things to watch Thursday, Oct. 3Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025.

Persons: Jeff Marks, Stocks, Dow, Beer, Jensen Huang, Blackwell, Eli Lilly, Morgan Stanley, Oppenheimer, Levi Strauss, Levi, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Constellation Brands, Modelo, Corona, Constellation, Nvidia, CNBC, Club, Bank of America, Devices, Amazon, Deutsche Bank, Costco, Dockers, Barclays, PepsiCo, Jim Cramer's Charitable Locations: Northern New Jersey, Europe, Americas

☆ Stocks making the biggest moves midday: Hims & Hers Health, Joby Aviation, Levi Strauss and more
▼ + stars: | 2024-10-03 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

EVgo — Shares soared 55% after the electric vehicle charger company received a $1.05 billion conditional loan from the Department of Energy. Hims & Her Health had previously developed compound versions of the drugs to take advantage of the shortage. Joby Aviation – Shares dropped more than 7%, paring back gains made in the previous session. Palantir recently announced that it's partnering with Edgescale AI to deliver Live Edge, a platform that will utilize artificial intelligence for manufacturing, utilities and other areas. Investors see both Vistra and Constellation as becoming key supporters of data center growth for developing tech companies' artificial intelligence technologies.

Persons: Bill Peterson, Eli Lilly, paring, Joby, Levi Strauss, Levi, Jensen Huang, CNBC's, Blackwell, Henning Cosman, Palantir, Sundar Pichai, Yun Li, Lisa Kailai Han, Hakyung Kim Organizations: Department of Energy, JPMorgan, U.S . Food, Drug Administration, Toyota, Dockers, Wolfspeed, Mizuho, Nvidia, Barclays, Constellation Energy, Nikkei, Investors Locations: U.S, China

☆ Stocks making the biggest moves premarket: Nvidia, Levi Strauss, EVgo and more
▼ + stars: | 2024-10-03 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +2 min

EVgo — Shares advanced more than 9% after JPMorgan upgraded the electric vehicle charging company to overweight . Levi Strauss — Shares plunged 12% after the denim maker trimmed its full-year revenue guidance and delivered fiscal third-quarter revenue that missed analysts' expectations. Constellation Brands — The beverage company rose slightly on the back of better-than-expected fiscal second-quarter earnings. Revenue of $2.92 billion, however, marginally missed expectations. Stellantis — The automaker was down more than 3% in the premarket after a Barclays downgrade to equal weight from overweight.

Persons: Mizuho, Jensen Huang, CNBC's, Blackwell, Eli Lilly, Bill Peterson, Levi Strauss —, Stellantis, Henning Cosman, — CNBC's Brian Evans, Lisa Han, Jesse Pound, Sean Conlon Organizations: Mizuho, Nvidia –, U.S . Food, Drug Administration, JPMorgan, Dockers, Constellation Brands, Barclays Locations: U.S

☆ 3-Stock Lunch: Nike, Humana & Eli Lilly
▼ + stars: | 2024-10-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3-Stock Lunch: Nike, Humana & Eli LillyAnthony Forcione, Rockland Trust VP, joins 'Power Lunch' to discuss stock plays for three stocks.

Persons: Eli Lilly Anthony Forcione Organizations: Nike, Humana, Rockland Trust

☆ Here are JPMorgan's top stock picks heading into October
▼ + stars: | 2024-10-02 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

For October, the additions include Best Buy and Carmax , while Wayfair , CarGurus and First Citizens BancShares are among those removed. The bank cited positive existing home sales, and an expansion in AI adoption, believing Best Buy will see continued growth in average selling prices . Analyst Christopher Horvers says Best Buy will increase its profitability over time, noting an uptick in operating margins to 5% from last year's 4.1%. He has an overweight rating on the stock, and his price target of $111 implies more than 9% upside from Tuesday's close. The bank's price target for Schwab implied about 22% upside and for Ulta Beauty about 18% potential appreciation, based on Tuesday's close.

Persons: JPMorgan's, Christopher Horvers, BBY, Eli Lilly, Lilly, Charles Schwab, Schwab Organizations: JPMorgan, Nasdaq, Dow Jones, Wall, AT, TPG Locations: Israel, Richland , Minnesota, Dallas, DirectTV, Lilly, Ireland

☆ Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
▼ + stars: | 2024-10-02 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of its pipeline. Lilly says the facility will be the first of its kind to combine research and production in a single location. It will be near a $9 billion manufacturing complex Lilly is building in Lebanon, Indiana, to produce pharmaceutical ingredients like tirzepatide, the active ingredient in Mounjaro and Zepbound.

Persons: Eli Lilly, Mounjaro, Lilly, David Ricks, –, Dan Skovronsky Organizations: Lilly, Foundry, Indianapolis, Novo Nordisk's Ozempic Locations: Indianapolis, Lebanon , Indiana, tirzepatide

☆ Eli Lilly CEO: We have 11 pipeline projects in obesity
▼ + stars: | 2024-10-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO: We have 11 pipeline projects in obesityCNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.

Persons: Eli Lilly, CNBC's Angelica Peebles, Eli Lilly's

☆ Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound caught up in East Coast trade shutdown
▼ + stars: | 2024-10-01 | by ( Lori Ann Larocco | ) www.cnbc.com time to read: +3 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTAn Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bills of lading, the digital receipts of freight containers, show that the delivery mechanisms for insulin and weight-loss drugs rely on East Coast ports for incoming trade. "Novo Nordisk and Eli Lilly are both heavily reliant on the Port of Norfolk," said William George, director of Research at ImportGenius, which tracks the customs data. Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. Bloomberg | Bloomberg | Getty ImagesAn Eli Lilly spokesperson said it does not discuss the details of its external supplier relationships.

Persons: Eli Lilly, Eli Lilly — Ozempic, William George, George, Dennis Monts Organizations: Bloomberg, Getty, Novo Nordisk, ILA, Nordisk, Research, U.S . Senate, CNBC, Nuco Logistics Locations: New England, Texas, U.S, lading, East Coast, Port of Norfolk, ImportGenius, Norfolk, airfreight, Hillerod, Denmark, Monts

☆ GE Healthcare has been an under-the-radar winner — and a new catalyst just arrived
▼ + stars: | 2024-09-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

Wall Street currently sees GE Healthcare earning $6.72 per share in 2028, according to FactSet, up from $4.25 projected this year. GE Healthcare has been a stock we've been battling since its steep slide during the second quarter. That dynamic — coupled with the positive China stimulus announcements in recent days — turned GE Healthcare into one of our top-performing stocks in the third quarter . A PET scan using Flyrcado has better diagnostic efficacy than SPECT scans, according to GE Healthcare. GE Healthcare may also see a recovery in its China business due to the roll out of medical-focused stimulus spending .

Persons: Wells, Flyrcado —, Wells Fargo, Flyrcado, FactSet, Jim Cramer, —, Jim, Leqembi, Eli Lilly, Stifel, Jim Cramer's, Yi Haifei Organizations: GE Healthcare, GE, Food and Drug Administration, Wall, FDA, Federal, Club, CDC, Management, CNBC, Fair for Trade, Services, China National Convention Center, China News Service, Getty Locations: China, U.S, Beijing

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Insider Today: Austin's genius housing fix
▼ + stars: | 2024-09-28 | by ( Joi-Marie Mckenzie | ) www.businessinsider.com time to read: +7 min

This week's dispatchThe high cost of weight-loss drugsiStock; Rebecca Zisser/BIWhy are two popular weight-loss drugs — Wegovy and diabetes medication Ozempic — so expensive in the US? Patients also bargain-hunt for cheaper weight-loss drugs online, or try to use manufacturer-issued coupons. See the full listiStock; Rebecca Zisser/BIDeals we loveCalling all Madewell shoppers: The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York City.

Persons: —, you've, Shailene Woodley, George Clooney, Rebecca Zisser, Ozempic, Lars Fruergaard Jorgensen, Sen, Bernie Sanders, it's, Gabby Landsverk, Ro, Henry Meds, Eli Lilly, Stefania Pelfini, Jenny Chang, Rodriguez, BI Marie, Mangin, Yellowstone Joey Hadden, Jackson, Wyoming's, Natalie Ammari, Zers, Austin, Tyler Le, Dan DeFrancesco, Jordan Parker Erb, Lisa Ryan, Amanda Yen, Grace Lett Organizations: Business, Service, Novo Nordisk, Federal Trade Commission, FDA, copycats, BI, Yellowstone, Austin, Lone Star, Disney, Pixar, British, Netflix, Insiders Locations: Washington ,, Germany, New York City, New York, Chicago

☆ Move aside, AI: None of our top 5 stocks in the third quarter are in tech
▼ + stars: | 2024-09-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

The best-performing Club stocks during the topsy-turvy third quarter are all outside the "Magnificent Seven" and AI-winner complexes. Starbucks: 25.2% New CEO Brian Niccol is the reason why Starbucks' stock is on the list. Best Buy: 18.6% The electronics retailer is another rate-cut winner: More people moving means more purchases of appliances and TVs. In fact, the reasons to own Best Buy are underappreciated by investors, JPMorgan analysts said in a note to clients Friday. Like Stanley Black & Decker and Best Buy, Home Depot is a beneficiary of increased housing sector activity.

Persons: —, Stanley Black, Decker, Brian Niccol, Eli Lilly, Lilly, there's, Jim Cramer's, Jim Cramer, Jim, Donald Allan , Jr, Chris Taylor Organizations: Reserve, Starbucks, Deutsche Bank, GE Healthcare, Novo Nordisk, Abbott Laboratories, Abbott Labs, GE, JPMorgan, CNBC, The New York Stock Exchange, NYSE Global Locations: U.S, China

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ How we're thinking about 7 portfolio stocks with ties to OpenAI after its latest shakeup
▼ + stars: | 2024-09-26 | by ( Morgan Chittum | ) www.cnbc.com time to read: +11 min

We're taking a keen interest because several stocks in the Club portfolio have ties to the startup behind ChatGPT. Co-founder Ilya Sutskever, who had been chief scientist, also left earlier this year and launched a new AI startup. Microsoft Microsoft got the first-mover advantage among big tech firms because of its early investment in OpenAI. As of now, we still haven't heard much about Lilly's exact plan to utilize OpenAI's technology. OpenAI CEO Sam Altman speaks during the Microsoft Build conference at Microsoft headquarters in Redmond, Washington, on May 21, 2024.

Persons: OpenAI, Sam Altman's, There's, Mira Murati, she's, Bob McGrew, Barret Zoph, Altman, Ilya Sutskever, it's, here's, ChatGPT, Jim Cramer, Jim, That's, —, OpenAI's, Jensen Huang, Nikesh Arora, Morgan Stanley Morgan Stanley, Morgan, Eli Lilly Eli Lilly, Eli Lilly's, Einstein, Marc Benioff, Jim Cramer's, Sam Altman, Jason Redmond Organizations: Club, Microsoft, Nvidia, Reuters, CNBC, Apple Intelligence, Apple, Bloomberg News, Street, Microsoft Microsoft, Blackwell, Palo, Palo Alto Networks, Employees, OpenAI, Barclays, Jim Cramer's Charitable, AFP, Getty Locations: OpenAI, Redmond, Washington, Palo Alto, Redmond , Washington

Search resuls for: "lilly"

25 mentions found